Novartis Defends Hypertension Patent Against Teva Claims
Novartis has pushed back against Teva's invalidity claims over a supplementary protection certificate that extends protection for a hypertension treatment, accusing the generic drugs giant of preemptively filing claims before infringing...To view the full article, register now.
Already a subscriber? Click here to view full article